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Abstract
Background—The goals of asthma treatment include preventing recurrent exacerbations. Yet
there is no consensus about the terminology for describing or defining “exacerbation,” or about
how to characterize an episode’s severity.
Objective—National Institutes of Health (NIH) institutes and other federal agencies convened an
expert group to propose how asthma exacerbation should be assessed as a standardized asthma
outcome in future asthma clinical research studies.
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Methods—We utilized comprehensive literature reviews and expert opinion to compile a list of
asthma exacerbation outcomes, and classified them as either core (required in future studies),
supplemental (used according to study aims and standardized), or emerging (requiring validation
and standardization). This work was discussed at an NIH-organized workshop in March 2010 and
finalized in September 2011.
Results—No dominant definition of “exacerbation” was found. The most widely used definitions
included 3 components, all related to treatment, rather than symptoms: (1) systemic use of
corticosteroids, (2) asthma-specific emergency department visits or hospitalization, and (3) use of
short-acting β-agonists (SABAs) as quick-relief (sometimes referred to as “rescue” or “reliever”)
medications.
Conclusions—The working group participants propose that the definition of “asthma
exacerbation” be “a worsening of asthma requiring the use of systemic corticosteroids to prevent a
serious outcome.” As core outcomes, they propose inclusion and separate reporting of several
essential variables of an exacerbation. Further, they propose the development of a standardized,
component-based definition of “exacerbation” with clear thresholds of severity for each
component.
Keywords
Asthma exacerbations; severity of acute asthma; asthma outcomes; urgent asthma care
INTRODUCTION
Asthma clinical research lacks adequate outcomes standardization. As a result, our ability to
examine and compare outcomes across clinical trials and clinical studies, interpret
evaluations of new and available therapeutic modalities for this disease at a scale larger than
single trial, and pool data for observational studies (eg, genetics, genomics,
pharmacoeconomics) is impaired.7 Several National Institutes of Health (NIH) institutes that
support asthma research (the National Heart, Lung, and Blood Institute [NHLBI]; National
Institute of Allergy and Infectious Diseases [NIAID]; National Institute of Environmental
Health Sciences; and the Eunice Kennedy Shriver National Institute of Child Health and
Human Development), as well as the Agency for Healthcare Research and Quality, have
agreed to an effort for outcomes standardization. This effort aims at (1) establishing standard
definitions and data collection methodologies for validated outcome measures in asthma
clinical research with the goal of enabling comparisons across asthma research studies and
clinical trials and (2) identifying promising outcome measures for asthma clinical research
that require further development. In the context of this effort, 7 expert subcommittees were
established to propose and define outcomes under 3 categories—core, supplemental, and
emerging:
• Core outcomes are identified as a selective set of asthma outcomes to be considered
by participating NIH institutes and other federal agencies as requirements for
institute/agency-initiated funding of clinical trials and large observational studies in
asthma.
• Supplemental outcomes are asthma outcomes for which standard definitions can or
have been developed, methods for measurement can be specified, and validity has
been proven, but whose inclusion in funded clinical asthma research will be
optional.
• Emerging outcomes are asthma outcomes that have the potential to (1) expand and/
or improve current aspects of disease monitoring and (2) improve translation of
basic and animal model-based asthma research into clinical research. Emerging
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outcomes may be new or may have been previously used in asthma clinical
research, but they are not yet standardized and require further development and
validation.
Each subcommittee used the recently published American Thoracic Society (ATS)/European
Respiratory Society (ERS) Statement: Asthma Control and Exacerbations—Standardizing
Endpoints for Clinical Asthma Trials and Clinical Practice8 (hereafter referred to as the
ATS/ERS Statement) as a starting point and updated, expanded, or modified its
recommendations as the subcommittee deemed appropriate. Each subcommittee produced a
report that was discussed, modified, and adopted by the Asthma Outcomes Workshop that
took place in Bethesda, Md, on March 15 and 16, 2010. The reports were revised
accordingly and finalized in September 2011. The workshop’s recommendations in regard to
asthma exacerbations outcomes are presented in this article.
International guidelines consistently describe the goals of asthma treatment to include the
control of patients’ current symptoms and the prevention of recurrent exacerbations. Several
definitions of an asthma exacerbation and exacerbation severity have been put forth by
various groups, including the Global Initiative for Asthma (GINA),9 the NHLBI/National
Asthma Education and Prevention Program (NAEPP) Expert Panel Report 3 (EPR-3),10 and
the ATS/ERS Statement. According to EPR-3, “asthma exacerbations are acute or subacute
episodes of progressively worsening shortness of breath, cough, wheezing, and chest
tightness—or some combination of these symptoms” (pp 374-5). Exacerbations are
characterized by decreases in expiratory airflow that can be documented and quantified by
simple measurement of lung function (spirometry or peak expiratory flow [PEF]).
The GINA guidelines define “acute exacerbations” (asthma attacks or acute asthma) as
“episodes of progressive increase in shortness of breath, cough, wheezing, or chest tightness,
or some combination of these symptoms, accompanied by decreases in expiratory airflow
that can be quantified by measurement of lung function” (p 69). These guidelines also define
exacerbations as acute and severe loss of control that requires urgent treatment. The GINA
guidelines refer to the severity of exacerbations but do not define exact criteria by which to
distinguish severity levels.
The recently published ATS/ERS Statement on the standardization of outcomes defined
“exacerbations” as “events characterized by a change from the patient’s previous status” (p
61). The task force stratified its definition by severity:
• Severe asthma exacerbations are events that require urgent action on the part of the
patient and physician to prevent a serious outcome, such as hospitalization or death
from asthma. The occurrence of severe asthma exacerbations should be used as a
marker of poor asthma control. The definition should include at least 1 of the
following:
a. Use of systemic corticosteroids (tablets, suspension, or injection), or an
increase from a stable maintenance dose, for at least 3 days. For
consistency, courses of corticosteroids separated by 1 week or more
should be treated as separate severe exacerbations.
b. A hospitalization or emergency department (ED) visit because of asthma,
requiring systemic corticosteroids.
• Moderate asthma exacerbations are events that should result in a temporary change
in treatment, in an effort to prevent the exacerbation from becoming severe. A
moderate exacerbation should include 1 or more of the following: deterioration in
symptoms, deterioration in lung function, and increased use of short-acting β-
agonist (SABA) bronchodilator. These features should last for 2 days or more, but
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not be severe enough to warrant systemic corticosteroid use and/or hospitalization
or ED visits for asthma.
The Asthma Exacerbations Subcommittee identified definitions of exacerbations through
literature searches, review of documentation from phase III clinical trials (for both adults
and children) registered on clinicaltrials.gov, and published reports from NIAID and NHLBI
clinical research networks. The search identified 27 pediatric citations (including 2 study
design papers)11–37, 47 adult study citations,38–82 and 11 articles related to specific
exacerbation measures. Excluding studies that did not clearly focus on exacerbation, a total
of 65 studies (34 phase III and 31 NIH consortia studies) were included in this review.
In developing its recommendations, the subcommittee conducted independent reviews for
pediatric and adult populations. Further distinctions within the adult and pediatric groups
also need to be made, because the clinical interpretation of significance of an exacerbation
may be different for various age groups. Our report discusses in more details issues unique
to children aged 0–4 years and children aged 5–11 years.
Outcomes for children aged 12 years and older tended to be aggregated with adult outcomes
in the literature, making specific conclusions for adolescent populations more difficult.
Therefore, recommendations for adolescents (aged 12–17 years) are incorporated within the
adult recommendations. However, further work studying adolescents, an age group that is
developmentally distinct from older and younger ones, is important83), and we encourage
reporting of outcomes by age groups that separate adolescents from adults (12–17 years and
≥18 years).
Similarly, older adults with asthma (aged ≥65 years) present unique diagnostic and
management issues.84 Older adult patients have more difficulty using inhalers, peak flow
meters, and undergoing spirometry because of physical (eg, arthritis, visual) and cognitive
impairments and memory issues.85–88 The diagnosis of exacerbations is also more
complicated in this population, given poor perception of symptoms, reduced expectations
with regard to activity level, and an increased risk of adverse effects from medications. The
subcommittee recommends that exacerbation outcomes in this age group also should be
reported separately. Given the paucity of data for this population, this approach will help in
the development of a database that will guide future asthma exacerbations research in older
adults.
ASTHMA EXACERBATIONS AS AN OUTCOME MEASURE
Definition and Methodology for Measurement
Almost no 2 studies define “asthma exacerbation” in the same way. The most commonly
included exacerbation outcomes were the need for systemic corticosteroids, urgent
unscheduled care, specifically ED or urgent care (UC) visits, and hospitalizations for
asthma.
The subcommittee proposes the following definition, primarily based on the ATS/ERS
Statement: “An exacerbation is a worsening of asthma requiring the use of systemic
corticosteroids (or for patients on a stable maintenance dose, an increase in the use of
systemic corticosteroids) to prevent a serious outcome.” The term “exacerbation” should
be distinguished from the terms “not well controlled asthma” or “uncontrolled asthma,”
which are measures of chronic disease activity (see the Composite Scores of Asthma Control
article).
Fuhlbrigge et al. Page 4













Core Outcome Measures for Exacerbations
The above definition does not include detailed aspects of an asthma exacerbation that
describe levels of severity, characterize the nature of the exacerbation, or relate to its
outcome. However, information on the range of events associated with an exacerbation, such
as an ED or UC visit, a hospitalization, an intensive care unit (ICU) stay, intubation, or
death should be outlined. Each type of event has unique biases that affect the rate observed
in different healthcare settings and populations. Inclusion of all events under a combined
outcome definition is possible, but information on the occurrence of each type of event
should always be provided to allow for more in-depth analysis and for better comparisons
between independent trials or studies. Therefore, the subcommittee recommends that the
core exacerbation outcomes that need to be reported in all asthma clinical trials and in all
age groups are the following:
1. All worsening asthma events in which systemic corticosteroids were initiated or
increased to prevent a serious outcome, including use of systemic corticosteroids in
association with any form of healthcare provider encounter
2. All asthma-specific ED or UC visits that involved treatment with systemic
corticosteroids
3. All asthma-specific hospitalizations that involved treatment with systemic
corticosteroids
4. All asthma-specific ICU admissions or intubations
5. All deaths (all cause and asthma related)
We agree with the ATS/ERS Statement definition requiring 3 days of systemic
corticosteroids for an event to qualify as an exacerbation in adult/adolescent populations.
Three days, as the lower limit of the recommended duration of treatment, is also based on
the EPR-3 guidelines. In the pediatric population, we do not include the requirement for 3
days of systemic corticosteroids to define an event as an exacerbation, because evidence in
pediatric acute-care supports the use of only 1–2 days of dexamethasone to achieve better
adherence and similar outcomes.89–91 The literature on the use of 1–2 days of
dexamethasone in the treatment of exacerbations is limited to pediatric populations, and the
requirement for 3 days of systemic corticosteroids among adults is recommended until this
practice has been evaluated in adolescent/adult populations. We further propose that the total
corticosteroid dose used in the treatment of an exacerbation (mg [milligrams]/patient/unit of
time, and duration of treatment) be reported as an attribute of the severity of an
exacerbation.
The subcommittee’s recommendations, with respect to core outcomes, also differ from the
ATS/ERS Statement in the following areas:
• The subcommittee does not endorse severity stratification in the core outcome
definition. There is not a validated way to define the lower threshold of moderate
exacerbations and to distinguish a moderate exacerbation from loss of chronic
asthma control. Therefore, severity stratification is not recommended as a core
outcome. In addition, possible confusion between the use of severity to describe the
underlying severity of disease, as opposed to the severity of exacerbations, can
arise. Further, severity of an exacerbation can refer to 2 distinct phenomena: (1) the
intensity of symptoms in general or (2) the magnitude of individual features, such
as the severity of airway obstruction. If a gradation of exacerbations is to be
utilized, the terminology needs to be unambiguous.
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• The subcommittee recommends that exacerbation outcomes within the adult
population be reported separately for adolescents (aged 12–17 years) and older
adults (aged ≥65 years of age).
• The subcommittee recommends separate reporting of deaths. There is debate over
whether all-cause mortality or asthma-specific mortality is the more appropriate
outcome to measure in asthma clinical trials. The validity of disease-specific
mortality as an outcome rests on the assumption that the cause of death can be
accurately determined and documented. This assumption has been challenged by
studies that evaluate the accuracy of death certificates.92, 93 In contrast, all-cause
mortality does not rely on assumptions regarding the cause of death and will
capture deaths including unexpected fatal side effects of medical care. All-cause
mortality as an outcome measure has been increasingly used in clinical trials.94, 95
Therefore, the subcommittee recommends that both all-cause and asthma-specific
mortality be reported.
Exacerbation outcomes are commonly reported in several ways, with multiple measures and
multiple denominators used within a given study. Time to first event and rate of occurrence
(number per patient per time interval) are the most frequently used methods of measuring
exacerbations. The ATS/ERS Statement recommends the usage of both these methods.
Analysis of time to first exacerbation minimizes the effect of differential dropout and of
individual subjects with multiple exacerbations. However, analysis of the rate of
exacerbations (reported as “number/patient/year”) is the most useful method for comparing
patient populations. Other potential methods include the number of exacerbations and the
percentage of the population with an event.
The subcommittee recommends reporting exacerbations as the rate of events per participant
per year in all asthma clinical trials for both adult and pediatric populations. The preferred
method for reporting the rate is the weighted mean rate, which is obtained by pooling all the
exacerbation events in a given treatment group of a trial and dividing by the total person-
time in that group. In addition to the overall exacerbation rate, the subcommittee
recommends that the rate of the individual types of events described above (ie, ED or UC
visits, hospitalizations, ICU admissions or intubations, deaths) also be reported
independently, to allow comparison between studies. It is important to emphasize that
drawing inferences from summary statistics between groups can be problematic, because
event count distributions are often skewed and have a large proportion of zeros. Sample size
and data distribution should be evaluated to ensure that appropriate analysis measures are
used.96, 97 Providing the median and the interquartile range of count data, in addition to
reporting the mean, gives greater insight into data distribution.98
Core Measures to Characterize Study Populations
Exacerbations constitute a distinct and important clinical characteristic of asthma, and the
prior history of exacerbations should be regarded as a core outcome in the description of the
population that participates in a clinical trial or an observational study of asthma. The
history of an exacerbation in the prior 12 months is 1 of the strongest predictors of future
exacerbations.99–102 Lieu and colleagues observed that having filled a prescription for
systemic corticosteroid or having had a hospitalization during the prior 6 months was
associated with increased risk of future admission for asthma.103 The history of past
exacerbation can be easily and reliably obtained, especially when defined as an event
requiring the use of systemic corticosteroids, an ED or UC visit, or a hospitalization.
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Supplemental Measures to Characterize Asthma Exacerbations in Acute-Care Setting
Studies
Standardizing the characterization of exacerbations for acute intervention trials in the ED,
UC, or hospital setting (as opposed to the use of exacerbations to characterize a population)
was not the focus of the subcommittee’s work. However, national guidelines recommend
objective measures of lung function to accurately assess the level of airway obstruction.
Forced expiratory volume in 1 second (FEV1) is used to categorize the severity of an
exacerbation for clinical trials that focus on the acute management of these events. For this
reason, the subcommittee has included FEV1 as a supplemental outcome for characterizing
the severity of acute asthma exacerbations in acute intervention trials in adolescent and adult
populations. In addition, the subcommittee considers the FEV1 response to SABA as an
emerging outcome for subject characterization of adults and adolescents in acute-care setting
studies. FEV1 or other lung function measures are frequently difficult to obtain in young
children, especially in the setting of an acute exacerbation. Several clinical scores have been
developed and validated for use in the clinical management of acute exacerbations.1–6 These
measures may have a role in clinical research focused on the ED setting and on
characterization of subjects potentially enrolled in studies. The subcommittee recommends
these instruments as supplemental outcomes for this type of study. These measures have not
been validated in adolescent or adult populations, and therefore have not been included for
the older age groups.
Medical and Scientific Value
Management and prevention of asthma exacerbations is a key focus of asthma care, patient
action plans, and the Healthy People 2010 objectives. Exacerbations can be life-threatening
and can result in costly utilization of emergency care: Between 35% and 50% of medical
expenditures for asthma have been attributed to acute exacerbations.104 A definition of
exacerbation that includes an intervention, such as the use of systemic corticosteroids, an ED
or UC visit, or a hospitalization has clinical relevance and, as noted in the ATS/ERS
Statement, is “intuitively valid.” The frequency of exacerbations requiring intervention with
systemic corticosteroids has been correlated in observational studies with the designation of
persistent, rather than intermittent, asthma105, 106 and is 1 of the central components
distinguishing intermittent from persistent asthma in the EPR-3 guidelines.
Reliability
The validity of a measure of an exacerbation cannot be judged by repeatability, since an
exacerbation, unlike a given biomarker, cannot be measured twice within a short period of
time to assess its variability. Both systemic corticosteroid use (initiated by patient or
clinician) and an ED or UC visit or a hospitalization require an assessment by the patient
and/or clinician that the event is severe enough to warrant intervention. However, the
decision to intervene depends on the patient’s perception and the provider’s judgment, with
remarkable variation across populations and healthcare settings.107 The decision to use
systemic corticosteroids may take into account patient or provider experience with side
effects. This may be particularly important for patients who have previously experienced
mood disturbance with oral systemic corticosteroids.108, 109 To gather information on the
thresholds that warrant intervention, the subcommittee recommends that prospective studies
clearly describe the parameters used in the decision to intervene (systemic corticosteroids
[oral and IV], ED or UC visits, and hospitalizations). Similarly, the factors (clinical,
psychological, and contextual) that contribute to patient and clinician decisions to use
systemic corticosteroids or that prompt UC utilization need to be further investigated. Future
research can focus on development of a checklist or standard format for collection of these
data.
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Our recommendation for reporting the rate of the individual components—systemic
corticosteroids (oral and IV), ED or UC visits, and hospitalization—will improve the ability
to compare findings across multiple trials. The factors that affect use of systemic
corticosteroids are not identical to those that influence the decision to visit the ED or to
admit a patient to a given healthcare setting, supporting the recommendation for separate
reporting of individual events. Finally, differences in the rate of exacerbations will occur,
depending on whether the outcome is obtained by self-report or captured prospectively in a
clinical trial and verified by review of records. Prior studies have shown differences in the
rate of events depending on how this information was obtained. When patient reports and
administrative data were formally compared, hospitalizations had the highest agreement
between the 2 data sources (93.9%), with lower values for ED visits (79.8%) and oral
systemic corticosteroid bursts (65.7%). The magnitude of the difference increases as the
number of events increases.110
In reporting the use of systemic corticosteroids, another factor that affects reliability is the
lack of quantification of corticosteroid dosage. Clinical trial reports do not always clarify
whether the corticosteroid dose was standardized in the protocol or left to physician
discretion. The subcommittee recommends that the dosage (milligrams of corticosteroid per
participant per unit time) and duration of treatment be included in the standard reporting of
asthma exacerbations (Table V). Whether the duration of treatment was prespecified or
dependent on the patient’s progress and how closely consecutive courses were handled
should be described.
Responsiveness
At a group level in clinical trials, use of systemic corticosteroids and healthcare utilization
has been found to be responsive to treatment (ie, these measures are expected to decrease
with effective interventions).
Validity and Associations
The construct validity of our proposed definition of exacerbation is supported by the
stipulation that it requires an intervention; the patient and caregiver agree that an
intervention is necessary. This suggests a clinically relevant outcome.
There is no gold standard against which to evaluate the criterion validity for any definition
of exacerbation. However, multiple clinical trials demonstrate convergent validity with other
measures of asthma-related health status.111–113 In addition, exacerbations are associated
with the risk of excess lung function decline in patients with asthma,114 demonstrating the
predictive validity of exacerbations.
Practicality
The use of systemic corticosteroids, an ED or UC visit, and hospitalizations are relatively
simple to record and are objective and quantifiable. Data on these events can be easily
obtained for both prospective and retrospective analyses. The reporting of the individual
components can be easily implemented and thus can be effective in standardizing study
results. The issue of discerning use of systemic corticosteroids with ED visits and
hospitalizations (especially with claims data), however, can be difficult.
Demographic Considerations
Age—As elaborated in the Introduction, there are differences in how exacerbations are
identified in various age groups. Distinctions between pediatric populations, adolescents
(who are developmentally distinct from older and younger individuals), and older adults
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from younger adults are important to consider. Therefore, the subcommittee recommends
reporting exacerbations separately for 5 age categories: 0–4, 5–11, 12–17, 18–64, and ≥65
years.
Socioeconomic status and geographic variation—Geographic variation in asthma
outcomes has been observed between neighborhoods within a city.115 These differences are
not adequately explained by race/ethnicity or by socioeconomic factors such as income and
insurance status. Differences in access to care, orientation to the healthcare system, and
health literacy also play a role. In addition, community characteristics such as poverty,
underemployment, limited social capital, substandard housing, and high violence and
community-level stress, more commonly encountered in the inner city, have been associated
with the risk of asthma exacerbations.22, 116, 117 The quality of ambulatory care, including
choice of long-term control medication and thresholds for admission, play a key role in
determining geographic differences in hospitalization rates for chronic childhood asthma.118
Children served by Medicaid tend to use the ED more frequently for asthma services than do
privately insured children. Racial/ethnic disparities in readmission rates persist after control
for comorbidities, payer type, and income.119 Racial and economic segregation are
particularly striking in the differences between inner-city and suburban populations noted in
published asthma exacerbation rates. These differences follow a distinct geographic pattern,
with the lowest rates in suburban residents (1.05/1000 child-years), followed by “other
urban” (2.99/1000 child-years) and inner-city residents (5.21/1000 child-years).120
Therefore, it is important to understand the broader societal context in which studies are
performed to compare results across studies. A standard composite measure to define
socioeconomic status (SES) for characterization of a given study population has not been
defined, but individual components that describe SES are well established. The
subcommittee recommends that SES be used as a supplemental outcome for the
characterization of study populations, but also calls for the development of a consistent
methodology for clinical trials to characterize SES and societal context of the population
being studied to facilitate comparison across studies. A consensus is needed on which
elements to measure, acknowledging that measurement for children may differ from that for
adults.
Limitations
As noted, 2 elements recur among the definitions for an asthma exacerbation: (1) use of
systemic corticosteroids and (2) a change in asthma health status severe enough to require a
visit to the ED or UC facility or a hospital admission. A third element frequently reported in
the pediatric literature is the increased frequency of SABA use. However, the threshold
criterion for distinguishing loss of asthma control from an asthma exacerbation has not been
defined and so cannot be included as a core outcome.
There is an emerging literature examining the use of increased doses of inhaled
corticosteroid, rather than systemic corticosteroid, as a method for delivering this class of
drug for acute exacerbations. However, randomized trials have failed to show decreased
exacerbation rates with doubling the inhaled corticosteroid dose,121, 122 and more recent
studies, using a 4-fold increase in inhaled corticosteroid, did not reach statistical significance
for the primary study endpoint.123 Therefore, the subcommittee recommends that the use of
a short course of high-dose inhaled corticosteroid as a criterion to define an exacerbation can
only be considered an emerging outcome. The subcommittee recommends conducting a
larger trial examining 4-fold increase in inhaled corticosteroid doses as a response to loss of
asthma control.
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Another potential limitation centers on the inclusion of UC visits with ED visits in defining
an asthma exacerbation. It is recognized that utilization patterns for UC clinics can vary
widely across locations, eg, in relation to waiting times in the closest ED, and according to
insurance patterns. In some areas, a UC clinic can function as an emergency treatment
venue, while in others, the UC visit resembles an outpatient encounter. Conversely, many
UC clinics have limited ability to accept underinsured patients, and many of these patients
(even with low acuity) may go to the ED. In sum, accurately differentiating UC visits from
ED visits is not possible in many healthcare settings. Therefore, the subcommittee
recommends combining UC and ED visits in both the definition and reporting of asthma
exacerbations. The subcommittee concludes that the use of systemic corticosteroids should
be the defining criterion, regardless of venue of care.
Finally, accurately determining when asthma-related hospitalization or ED visits are
associated with the use of systemic corticosteroids can be difficult. While the recommended
definition of an asthma exacerbation includes an asthma-related hospitalization or ED visit
requiring systemic corticosteroids, in some studies, it will not be possible to distinguish the
healthcare utilization events that include the use of systemic corticosteroids from those
events that do not.
Priority for NIH-Initiated Clinical Research
The subcommittee acknowledges that there is no fully validated definition of an asthma
exacerbation. However, our recommended definition contains central elements of the EPR-3
guidelines and the ATS/ERS Statement, and is quantifiable and objective. The methods for
measuring and reporting are the most standardized. Multiple clinical trials have used this
definition of “exacerbation” as an outcome; evaluation of exacerbations, using this
definition with other measures of asthma health status, has demonstrated concurrent validity.
As an example, an analysis of a large, longitudinal study of children confirmed a
relationship between the severity of airflow obstruction and the risk of exacerbations.105 In
addition, at a group level, the use of systemic corticosteroids and/or UC utilization has been
found to be responsive to treatment.
The proposed definition is clinically relevant and has significant scientific value. The rate of
exacerbations, as defined, has analytic properties that allow easy comparison. Reliability of
the definition has limitations when used in retrospective analyses; however, in prospective
trials the definition can be operationalized to promote its consistency among studies. The
proposed definition has been shown to be responsive to treatment with both pharmacologic
and nonpharmacologic interventions. Although there is no gold standard by which to assess
its criterion validity, there is evidence for construct and predictive validity. Further, it is a
measure that is practical and relatively easy to record. Issues related to culture, SES, access
to care, and differences in healthcare systems may affect its value, but the study methods
and procedures within prospective trials can help account for these effects.
FUTURE DIRECTIONS AND RESEARCH QUESTIONS
A Component-Based Definition of “Asthma Exacerbation”
Many definitions of “asthma exacerbation” combine multiple components, such as change in
symptoms, lung function, and SABA use. The subcommittee believes that this approach
should be pursued with the goal of developing and validating a standard, component-based
definition. There has been increasing awareness of heterogeneity of the underlying disease
processes in asthma. Recent reports have highlighted the importance of different asthma
phenotypes and their natural history.124–129 As these phenotypes may alter the way
individual patients present and how they respond to intervention, characterization of
patients’ phenotypes will become increasingly important in the development of targeted
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therapies. Even in patients with well-characterized asthma, the relationship between the
underlying disease processes and their clinical manifestations is not strong. At a group level,
pathophysiological markers, such as sputum eosinophils and airway hyperresponsiveness, do
not necessarily correlate strongly with one another or with patients’ clinical features.130 This
lack of correlation suggests that each component adds independent information about a
patient’s underlying phenotype and highlights 2 challenges: how to assess patients with
asthma and how to judge treatment response. In clinical trials, a wide array of outcome
measures has been used to evaluate asthma. Yet there has been no agreement on the relative
importance or weight of any of these measures. Therefore, reaching consensus about the
components that should be included in the definition of exacerbation is a question worthy of
further investigation.
We discuss each of the following possible components of a future component-based
definition of asthma exacerbations in more detail below: symptoms, SABA use, physiology,
biomarkers, quality of life, and composite measures of asthma control.
Symptoms—The goal of asthma therapy is to minimize symptoms, optimize lung
function, and prevent exacerbations. The classic 4 symptoms typically are wheezing,
shortness of breath, cough, and chest tightness. However, asthma symptoms are nonspecific,
and their occurrence and individuals’ perception of them vary among patients. Although
increased symptoms and SABA use are characteristic of exacerbations, there are currently
no validated criteria for the magnitude of change in symptoms that defines an asthma
exacerbation. In addition, it is difficult to establish explicit definitions for “exacerbation,”
given the range of values reported. A wide range of symptom score scales is available in the
literature, with ordinal scales ranging from 0 to 3, 10, and 12. Most studies distinguish
between daytime and nighttime symptoms and night waking. However, some instruments
ask a global question about “asthma symptoms” without further clarification, whereas in
other studies, the individual asthma symptoms of wheezing, dyspnea, chest tightness, and
cough are detailed separately. A frequent metric is the symptom-free day, asthma-free day,
or conversely, the asthma-symptom day, but the way the questions are asked about
individual symptoms influences the ability to satisfy criteria for a symptom-free day.
Symptom measures also vary in the way they either assess or distinguish among the
frequency, intensity, or impact of symptoms on normal activities. In pediatric assessments,
diary completion by the parent or caregiver rather than by the child also may lead to
underreporting. Further work to develop a symptom measure for inclusion in a component-
based definition of asthma exacerbation is encouraged.
SABA use—The use of SABA for quick relief may reflect the frequency and intensity of
symptoms and can be considered a surrogate measure for symptoms. The measure can be
quantified as the number of inhalations, or puffs, per day or of SABA-free days. However,
the use of SABAs also reflects the patient’s symptom tolerance and his or her usual level of
physical activity, which makes SABA as an outcome measure more subjective. In addition,
the routine dose of some SABAs can be 1 or 2 inhalations, and some SABA use is
anticipatory, which adds variability. For children, SABA use is often controlled by the
parent. However, the decision to use SABA for acute symptoms is a common criterion for
exacerbations in studies of asthma. In studies of adults, it was the most commonly reported
component after systemic corticosteroids use, ED or UC visits, and hospitalizations for
exacerbation, and it was included in 68% of the studies. A major problem is that the
threshold criterion for distinguishing between loss of control and an asthma exacerbation has
not been defined. Thresholds for SABA use as a definition for an exacerbation varied from
>3 to 12 puffs per day in pediatric studies and >4 to 16 puffs per day in adult studies.
Noteworthy are multiple, slight variations to capture a similar concept: The threshold for
increased SABA use was defined in 12 different ways in the reviewed literature. Therefore,
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more research on thresholds for increased use of SABA as a component of an asthma
exacerbation is required before this can be considered a core exacerbation outcome or can be
used as 1 of the elements of a component-based definition of asthma exacerbation.
Physiology—Exacerbations are characterized by a decrease in expiratory airflow that can
be documented and quantified by simple measurement of lung function (spirometry or PEF).
FEV1 is often cited as a recognized valid and reliable measure, but one that requires
regularly calibrated equipment and carefully trained technicians for accurate measurement.
Its use is not feasible in the very young, but it can be used in children aged 5 years and
older, adolescents, and adults. However, while FEV1 remains an important asthma outcome
measure, its use in defining exacerbations is less common.
A change in PEF has been used to define an exacerbation, with the level of required change
varying from 20% to 35%. In several studies, poor associations have been observed between
PEF criteria for exacerbation and clinician prescription of corticosteroids. In the Formoterol
and Corticosteroids Establishing Therapy International Study Group (FACET) study, 73%
of the exacerbations were identified clinically by the investigator rather than by a reduction
in morning PEF.54 Similarly, in the budesonide/formoterol combination therapy as both
maintenance and reliever medication in asthma STAY study, 87% of the exacerbations that
met the fall in PEF criteria were commonly discovered on retrospective analysis of diary
card data and did not result in a medical intervention.131 This calls into question the clinical
relevance of a change in PEF in prospectively defining an exacerbation. PEF has been
shown to be less sensitive in identifying exacerbations than FEV1. In 1 study, 31 treatment
failures were identified by a ≥20% fall in FEV1 compared with 7 for PEF (≤65% baseline, 2
of 3 consecutive measurements) or 4 with SABA use (≥8 puffs/day over baseline or 16
puffs/day in 48 hours). Similarly, using a ≥20% fall in FEV1 as the gold standard,
investigators compared the utility of PEF, symptoms, and SABA use as a marker of
treatment failure both used alone and used together.132 None of the measures successfully
discriminated patients with a fall in FEV1 of ≥20% from those without. Sensitivity and
specificity were generally poor (<80%) at all cutoff values. Additional studies that defined
treatment failures with multiple measures found that most treatment failures were
characterized by reduction in FEV1 or systemic corticosteroid use.62, 66
Finally, because of the high proportion of retrospectively completed entries, data from paper
PEF diaries should be interpreted with caution in the analysis of exacerbations.133
Electronically recorded PEF data need to be considered in future validation studies because
they may be more reliable. Identification of the level of change in PEF that can be included
in a component-based definition of exacerbation may be valuable. In addition, FEV1 is a
recognized, valid, and reliable measure, and remains an important asthma outcome measure,
but its use in defining exacerbations is not currently recommended. However, its use in a
composite measure defining exacerbations should be considered.
Biomarkers—Biomarkers are useful in assessing and studying the biology of exacerbation,
and can be included in prospective studies, within the limits of the technical capability of the
tests, such as fractional exhaled nitric oxide (FeNO), sputum eosinophils, and exhaled breath
condensate analytes. However, biomarkers do not currently have a role in defining or
diagnosing exacerbation. For example, clinical trials evaluating the use of FeNO in
predicting asthma exacerbation and adjusting therapy have reported variable results. Further
evaluation is needed to define the role of FeNO in guiding asthma management.
Quality of life—Asthma-related quality of life is a global measure of the impact of asthma
from the patient’s perspective, including the impact of exacerbations. The patient’s
perception of the burden of disease may be completely different from the clinician’s and
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may vary according to the patient’s circumstances and expectations. While measuring
health-related quality of life can add valuable information for improving assessment of the
impact of asthma, and asthma-related quality of life has been used for validation of other
asthma-related outcomes, quality of life cannot be recommended as a component for
defining exacerbations.
Composite measures for asthma control—The distinction between loss of asthma
control and a progression to exacerbation is blurred and characterized by vague and
inconsistently used terminology. The use of such measures to define an exacerbation is not
recommended.
Stratification by Severity
The EPR-3 guidelines note that acute exacerbations can be mild, moderate, or severe in any
category of persistent asthma. The ATS/ERS Statement on the standardization of outcomes
defines “moderate” and “severe exacerbation” but excludes “mild exacerbation” from their
recommendations. The ATS/ERS Statement excludes a definition of “mild exacerbation”
because it is hard to distinguish these episodes from the normal variation for the individual
patient or from transient loss of asthma control. Further, the ATS/ERS Statement’s
definition of “moderate exacerbation” is limited because it does not include objective
criteria to for the threshold values necessary to operationalize its use in clinical trials.
Terms such as “mild,” “moderate,” and “severe” represent categorical classifications that
require agreement on which clinical measures are used to classify severity, as well as
agreement on threshold criteria. Whether these focus on the frequency of night waking,
SABA use, or lung function values, setting thresholds that allow one to distinguish between
uncontrolled asthma and an exacerbation poses significant challenges. The majority of the
individual parameters that can assess asthma status are continuous traits, and identification
of threshold values or creation of categorical variables can be arbitrary. Further, the number
of days of change in status that are required to label something an exacerbation needs to be
determined.
Nevertheless, the concept of a moderate exacerbation has utility because early treatment of
asthma exacerbations is the best strategy for management. It is reasonable to consider a
definition of asthma exacerbation that includes one of lesser severity (ie, deterioration in
symptoms and/or lung function with increased SABA use but not severe enough to warrant
systemic corticosteroid use and/or a hospital visit). However, further investigation is needed
to define criteria to standardize the thresholds distinguishing uncontrolled asthma from a
moderate exacerbation for either prospective or retrospective clinical trials. Therefore,
severity classification of exacerbations is an emerging outcome.
Systemic Corticosteroid Dosing and Duration of Treatment
For oral systemic corticosteroid use, a potential problem with reporting in both retrospective
and prospective studies is the lack of quantification of dosage or duration of treatment. In
addition, trial reports do not always make it clear whether the corticosteroid dose was
standardized in the protocol or left to physician discretion. The most accurate measurement
of corticosteroid use is milligrams of corticosteroid taken per patient per unit of time and the
duration of therapy. The handling of closely consecutive courses also should be outlined.
It must be noted that many courses of corticosteroids are of a prespecified duration,
independent of how quickly a patient improves; in such instances, the total amount of
corticosteroid taken may not accurately reflect the severity of the event. However, as a first
step, recording the duration and total dosage given will improve understanding of these
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events and the ability to compare results across studies. This information will be less
available for retrospective studies but should be reported when possible.
For prospective studies, the factors (clinical, psychological, and contextual) that contribute
to patient and clinician decisions to use systemic corticosteroids or that prompt UC
utilization need to be further investigated. The subcommittee proposes as a first step the
development of a standardized format for capturing this information.
Factors Precipitating Exacerbations
Emerging science has emphasized the variability in the pathophysiology of asthma, which
manifests as different clinical phenotypes. Similarly, asthma exacerbations are precipitated
by different factors, such as viral infections or exposures to allergens and irritants.
Therefore, it is possible that exacerbation phenotypes may exist. It is further speculated that
the response to an intervention during an exacerbation differs depending on the precipitating
factor. To examine this concept of exacerbation phenotypes, the subcommittee recommends
the development of a standard reporting format for capturing information related to these
precipitating factors.
SPECIFIC ISSUES RELATED TO EXACERBATIONS AS AN ASTHMA
OUTCOME MEASURE IN PEDIATRICS
Definition and Methodology for Measurement
There are differences in the way exacerbations are currently measured in different age
groups. In addition to the use of systemic (or increase in inhaled) corticosteroids, other
frequently used measures for diagnosing an asthma exacerbation in a pediatric population
include documentation of respiratory signs and symptoms, symptom scores, use of SABA,
and response to SABA. Objective measures, including pulse oximetry, and exhaled FeNO
also have been used for defining exacerbations in children and characterizing the severity of
these exacerbations. Practical measures of lung function are not routinely available for
children aged 0–4 years, and there are notable individual variations in use of lung function
measures in children aged 5–11 years. The following sections discuss various definitions of
asthma exacerbations in children.
Asthma Exacerbations in Children Aged 0–4 Years
Asthma exacerbations in children aged 0–4 years are difficult to identify for several reasons.
Foremost, the differentiation of changes in daily symptoms from a potential cluster of
symptoms sufficient to be termed an exacerbation is based on the perception of the caregiver
and not the child. The threshold for symptom identification and initiation of therapy depends
on the education level and personality of the caregiver. Objective metrics to identify
exacerbations are difficult to determine and have not been used in large clinical trials. A
further complication in this age group is that wheezing from causes unrelated to asthma,
including viral respiratory infections, is common. Further research is needed to develop
reliable identification of different wheezing phenotypes and treatment responses to allow for
precise definitions of exacerbations in this age group.
Current asthma guidelines definitions for children aged 0–4 years—The EPR-3
asthma guidelines emphasize the importance of the physical examination and not objective
measurements in the assessment of an asthma exacerbation in preschool children. Use of
accessory muscles, inspiratory and expiratory wheezing, paradoxical breathing, cyanosis,
and tachypnea are all cited as signs of respiratory distress. The most important objective
measurement proposed is the percentage of available hemoglobin that is saturated with
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oxygen (SaO2), which, if less than 90%, can indicate serious respiratory distress. Lack of
objective improvement in the physical examination following treatment with SABA is given
as an indicator for hospitalization. Treatment with a systemic corticosteroid is recommended
early in an asthma exacerbation of a preschool child or infant.
The GINA guidelines define an exacerbation of asthma in children aged 5 years and younger
as an acute or subacute deterioration in symptom control that is sufficient to cause distress or
risk to health, necessitating a visit to a healthcare provider or requiring treatment with
systemic corticosteroids. Early symptoms of an acute exacerbation may include any of the
following: an increase in wheezing and shortness of breath; an increase in coughing,
especially nocturnal cough; lethargy or reduced exercise tolerance; impairment of daily
activities, including feeding; and a poor response to SABA medication.
Review of Definitions of “Exacerbation” in Clinical Trials
Two large NHLBI-funded clinical trials involving wheezing exacerbations have been
conducted in preschool children.30, 31 In the PEAK trial (Preventing Early Asthma in
Kids),30 participants aged 12–59 months with a positive asthma predictive index (an
indicator of risk factors for developing persistent asthma) received 2 years of inhaled
fluticasone or placebo, to determine whether the inhaled corticosteroid had an impact on
asthma-control days in year 3. Exacerbations were defined as a course of oral systemic
corticosteroids to control asthma-like symptoms.
In the AIMS (Acute Intervention Management Strategies) study,31 early signs of episodic
respiratory tract illnesses were treated with either inhaled budesonide or montelukast in
children aged 12 to 59 months, to prevent the development of an exacerbation. However,
like the PEAK trial, the AIMS study defined an exacerbation as an episode requiring the use
of oral systemic corticosteroids given according to a predetermined protocol.
A phase III industry-sponsored study compared the effectiveness of budesonide inhalation
suspension to montelukast over 52 weeks in children 2–8 years of age with asthma.26 The
mean age of study participants was 4.8 years. The primary endpoint in the trial was time to
first additional medication for worsening asthma within 52 weeks. Time to first asthma
exacerbation was a secondary endpoint and was defined as the time to either a doubling of
inhaled corticosteroids or an oral systemic corticosteroid burst. This study also defined mild
versus severe exacerbations: a mild asthma exacerbation was defined as the need for ≥3
doses of SABA on 4 of 7 consecutive days or as having nighttime awakenings caused by
asthma symptoms on ≥2 of 7 days during each of 2 consecutive weeks. A severe asthma
exacerbation was defined as one needing 6 doses of SABA in a 24-hour period, 10 doses of
SABA in a 48-hour period, or hospitalization for worsening of symptoms.
Summary for children aged 0–4 years—There is no well-validated objective
definition of an asthma exacerbation in preschool children. Available clinical trials use the
following definitions: (1) a burst of corticosteroids to control acute asthma-like symptoms,
(2) complex algorithms utilizing individual symptom profiles, or (3) symptoms that persist
despite treatment with a SABA. Specific thresholds for these definitions have not been well
established because of the small number of subjects studied and because of variations in
inclusion and exclusion criteria. The same constraints apply to the repeatability,
responsiveness, validity, and associations for each of the definitions used to date.
Subcommittee definition of “exacerbation” in children aged 0–4 years—An
exacerbation is a worsening of asthma requiring the use of systemic corticosteroids (or for
patients on a stable maintenance dose, an increase in the use of systemic corticosteroids) to
prevent a serious outcome. However, evidence in pediatric acute-care supports the use of
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only 1–2 days of dexamethasone to achieve better adherence and similar outcomes.89–91
Therefore, the requirement for 3 days of systemic corticosteroids to define an event as an
exacerbation for adults is not included in the definition of an exacerbation for children aged
0–4 years.
Outcome measures for asthma exacerbation in c hildren aged 0–4 years—The
subcommittee recommends that the core outcomes for asthma exacerbations in prospective
clinical trials for children aged 0–4 years should be the same as for adolescents and adults:
a. All worsening asthma events in which systemic corticosteroids are initiated or
increased to prevent a serious outcome (these include use of systemic
corticosteroids in association with any form of healthcare provider encounter)
b. All asthma-specific ED or UC visits that involve treatment with systemic
corticosteroids
c. All asthma-specific hospitalizations that involve treatment with systemic
corticosteroids
d. All asthma-specific ICU admissions or intubations
e. All deaths (all cause and asthma related)
Additional features characterize asthma exacerbations of preschool children and are
considered supplemental outcomes. These features include tachypnea (respiratory rate >60
per minute), hypoxemia (SaO2, <90% predicted), cough, and retractions, and are included in
a number of composite assessment tools, such as the Pediatric Asthma Severity Score
(PASS),3 Asthma Severity Score (ASS),1 Clinical Asthma Score (CAS),2 Preschool
Respiratory Assessment Measure (PRAM),5 Pulmonary Index (PI),4 and Pulmonary Score
(PS).6 For this age group, these tools can be used to assess the severity of an exacerbation in
ED and UC settings, and as outcome measures testing the effectiveness of an intervention.
The recommendations for reporting exacerbation outcomes are outlined in Table V.
Measures to characterize the study populations are important because they will enhance
analysis and interpretation of clinical trial or observational study outcomes and are listed in
Table III.
Asthma Exacerbations in Children Aged 5–11 Years
Children aged 5 years and older can be expected to provide information about symptoms,
and the majority can perform lung function testing and home monitoring of PEF. The
principles of medical therapies to relieve acute symptoms of asthma children in this age
group are similar to those used to treat adults. Collectively, this means that the quality of the
data that can be used in exacerbation definitions is similar to that obtained in studies of
adults.
We reviewed pediatric asthma treatment studies in which asthma exacerbation was used as
either a primary or secondary outcome. This review focused on identifying the prevalence of
the use of different measures for defining asthma exacerbations, as well as the supporting
evidence base. A total of 15 NIH-funded studies18, 20–27, 30, 31, 33, 35–37 and 5 phase III
industry-sponsored studies11, 13, 15–17 was identified that included children aged 5–11 years
(with some variation in upper and lower age limits). Six additional studies included children
aged 5–11 years together with adolescents.
Review of definitions of “exacerbation” in clinical trials—The review identified 4
main themes: (1) Exacerbation was seldom used as a primary outcome; (2) definitions for
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exacerbation were not always clearly stated in the protocols; (3) there was considerable
variability in the definitions; and (4) most of the definitions were composites of multiple
measures. A subset of studies (11 NIH studies and 4 industry-sponsored studies) provided
enough detail to assess specific criteria for defining exacerbation. As for adolescent and
adult populations, the most common definition for children aged 5–11 years was the use of
systemic corticosteroids, followed by hospitalization or ED visit. The frequency and
duration of SABA use; a drop in PEF; and symptoms such as wheezing, nocturnal waking,
and persistence of symptoms after treatment also were reported, but there was considerable
variation regarding whether and how these measures were reported within the trials.
The use of SABA in the context of acute worsening of symptoms of asthma is a historically
employed, almost universal criterion for asthma exacerbations within pediatric populations.
It is also used in EPR-3 to help define exacerbations. SABA use reflects a need for more
vigorous treatment and can be either a binary measure or a continuous measure. When a
continuous measure, SABA use can be expressed as the number of puffs or nebulizer
treatments in the course of a study period, the time to the first dose, or both. However, the
subcommittee only recommends SABA as an emerging outcome because usage patterns of
SABA reflect provider, patient, or caregiver judgment with remarkable variation in the
decision criteria. Better definition of these criteria is crucial in determining validity of this
measure. In addition, although this measure is commonly used, the cutoff values that define
an exacerbation have not been validated. For these reasons, the subcommittee recommends
SABA use as an emerging outcome in this age group.
Biomarkers offer some promise for defining exacerbations, including sputum assays, FeNO,
and assays of exhaled breath condensate. These samples are relatively easy to collect in
adolescents, and can be potentially collected in children aged 5–11 years. However, these
samples are difficult to collect in younger children. In general, they can help identify loss of
asthma control, identify patients at risk for exacerbations, shed light on the biology of an
exacerbation, and potentially aid the prognosis for resolution of disease. However, these
measures have not yet been validated for the purpose of defining an exacerbation.
Subcommittee definition of “asthma exacerbations” in children aged 5–11
years—The definition of asthma exacerbation for children aged 5–11 years is the same as
that for children aged 0–4. As is the case with the recommendation for young children (0–4
years), the requirement for 3 days of systemic corticosteroids to define an event as an
exacerbation is not included for children aged 5–11 years because evidence in pediatric
acute-care supports the use of only 1–2 days of injected dexamethasone to achieve better
adherence and outcomes similar to the use of oral systemic corticosteroids.89–91
Outcome measures for asthma exacerbations in children aged 5–11 years—
The core outcome measures for children aged 5–11 years are the same as those listed for
children aged 0–4. FEV1 is listed as a supplemental outcome for children age 5–11, when
feasible, whereas FEV1 is not a feasible measure for the 0–4 age group.
Future Directions and Research Questions Related to Pediatric Populations
Component-based definition of “asthma exacerbations”
As with adult and adolescent populations, the subcommittee believes that a component-
based definition of asthma exacerbation is also needed in studies involving populations aged
11 years and younger. It is not possible to predict at this point whether the ideal component
definition for asthma exacerbations will be the same for pediatric populations as for adults
or whether preschool children will require a definition different from that of older children.
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Currently, there are multiple components in the various definitions for “exacerbation,” but
there was little evidence to support a choice of 1 or more of these components as the best
definition. There is some evidence that composite definitions for exacerbations are better
indicators of treatment response than a single indicator; however, existing component-based
definitions have not been directly compared with one another. In addition, there is a lack of
consensus regarding specific criteria and cutoff values for individual components.
Establishing a component-based definition of asthma exacerbations to be used in future
clinical trials is an important task for the future.
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TABLE I
Recommendations for classifying a sthma exacerbation outcome measures for NIH-initiated clinical research



















visits (separate UC visits
when these can be
differentiated)
1 Systemic corticosteroids
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2 Any prior exacerbation
3 Any prior ICU
admission/intubation
4 SES of the study
population
















2 Short course of high-dose
inhaled corticosteroids as
a definition of an asthma
exacerbation
3 SABA use (with a
predefined cutoff value)











Call for new outcome
measures/instruments
1 Component-based definition of “exacerbation” with threshold values for each component
2 A standard format for characterizing an exacerbation by precipitating factor (eg, viral illness, allergen
exposure, pollutant exposure, medication nonadherence)
3 A standard format to define factors that contribute to the decision to use systemic corticosteroids or
seek UC
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ED, emergency department; FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; ICU, intensive care unit; NIH,
National Institutes of Health; SABA, short-acting β-agonist; SES, socioeconomic status; UC, urgent care.
*
Observational study designs include cohort, case control, cross sectional, retrospective reviews, and genome-wide association studies (GWAS),
and secondary analysis of existing data. Some measures may not be available in studies using previously collected data.
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TABLE II
Key points and recommendations for adult and adolescent populations
1 Recommended definition: An exacerbation is a worsening of asthma requiring the use of systemic corticosteroids (or for
patients on a stable maintenance dose, an increase in the use of systemic corticosteroids) to prevent a serious outcome.
2 Tremendous variation exists in the literature regarding the terminology for an asthma exacerbation. We identified 15 different terms
in use to refer to an asthma exacerbation, which makes comparison across studies problematic. An asthma exacerbation is rarely
defined by a single component diagnostic component, but when it is, treatment with systemic corticosteroids is the one most
commonly used. Variation in the way subjects with asthma present supports the use of a definition that includes multiple
components; yet little evidence exists to support a specific set of components or the thresholds for any individual component within
a given definition.
3 We found no consistent or dominant definition of “asthma exacerbation” in the literature. Most commonly, the definition for
“exacerbation” in adults who have asthma was based on 3 criteria: (1) the use of systemic corticosteroids, (2) healthcare utilization
that included an ED or UC visit or hospitalization; and (3) the use of SABAs as quick relief (sometimes referred to as “rescue” or
“reliever”) medication (with or without concurrent reference to asthma symptoms).
4 Variation exists in the way the severity of an exacerbation is classified. Most studies do not distinguish levels of severity. When
exacerbations are noted as “severe,” the definition typically includes initiation of systemic corticosteroid treatment and/or a
measure of ED or UC utilization or hospital admission.
5 The ability to distinguish between poorly controlled asthma and an exacerbation is difficult and is characterized by vague and
inconsistent terminology.
6 Standardized terminology, definition of severity levels, and precise operational definitions of the components that are used to
identify an exacerbation are needed.
7 Currently, biomarkers are not useful in defining an exacerbation. However, they may be useful in better understanding the biology
and mechanisms of exacerbation, and in defining the population at risk for it.
ED, emergency department; SABA, short-acting β-agonist; UC, urgent care.
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TABLE III
Recommendations for classifying a sthma exacerbation outcome measures for NIH-initiated clinical research



















3 Asthma-specific ED visits
(separate UC visits where





3 Asthma-specific ED visits
(separate UC visits when
these can be differentiated)
4 Asthma-specific ICU
admissions/intubations
























b. FEV1 (ages 5–
11 years, as
feasible)
2 Any prior exacerbation
3 Any prior ICU admission/
intubation
4 SES of the study
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2 Short course of high- dose
inhaled corticosteroids as a
definition of an asthma
exacerbation
3 SABA use (with a
predefined cutoff value) as
a definition of an asthma
exacerbation




5 Total dose and duration of
systemic corticosteroid use
None


























Call for new outcome
measures/instruments
1 Component-based definition of “exacerbations” with threshold values for each component
2 A standard format for characterizing an exacerbation by precipitating factor (eg, viral illness, allergen
exposure, pollutant exposure, medication nonadherence)
3 A standard format to define factors that contribute to the decision to use systemic corticosteroids or
seek UC
ASS, Asthma Severity Score1; CAS, Clinical Asthma Score2 ; ED, emergency department; FeNO, fractional exhaled nitric oxide; FEV1, forced
expiratory volume in 1 second; ICU, intensive care unit; NIH, National Institutes of Health; PASS, Pediatric Asthma Severity Score3; PI,
Pulmonary Index4; PRAM, Preschool Respiratory Assessment Measure5; PS, Pulmonary Score6; SABA, short-acting β-agonist; SES,
socioeconomic status; UC, urgent care.
*
Observational study designs include cohort, case control, cross sectional, retrospective reviews, and genome-wide association studies (GWAS),
and secondary analysis of existing data. Some measures may not be available in studies using previously collected data.
†
In older children who can perform these techniques.
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TABLE IV
Key points and recommendations for pediatric populations
1 Recommended definition: An exacerbation is a worsening of asthma requiring the use of systemic corticosteroids (or, for
patients on a stable maintenance dose, an increase in the use of systemic corticosteroids) to prevent a serious outcome. This
definition is the same for pediatric (aged 0–4 and 5–11 years) as for adult and adolescent populations. Although the use of SABA is
a more commonly employed criterion or factor for defining “exacerbation” in children, the threshold criterion for distinguishing
between loss of control and an asthma exacerbation has not been defined. Therefore, this criterion could not be included as a core
outcome.
2 Asthma exacerbations in children aged 0–4 years are particularly difficult to identify for several reasons. Foremost is the
consideration that the differentiation between changes in daily symptoms and a potential cluster of symptoms sufficient to be
termed an exacerbation is based on the caregiver’s perception of symptoms and not the child’s perception. The threshold for
symptom identification and initiation of therapy depends on the education level and personality of the caregiver.
3 Currently, biomarkers are not useful in defining “exacerbation.” However, for older children (aged 5–11 years), biomarkers may be
useful in better understanding the biology and mechanisms of exacerbation and in identifying the population at risk for
exacerbation.
4 Many physiological measures (ie, FEV1) and biomarker techniques (FeNO, induced sputum, and exhaled breath condensate) are
age dependent and difficult to use reliably in young children.
FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; SABA, short-acting β-agonist.
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TABLE V
Methods for reporting core and supplemental outcome measures for asthma exacerbations for all ages
For all outcome measures Report outcomes by:
1 Events for total study population





e. 65 years and older
Exacerbations Preferred:
1. Overall rate (number of events requiring systemic corticosteroids/participant/time interval
specified by study). Annual rates are preferred for studies of at least 12-month duration.
Annualization for shorter studies is not recommended.
2. Weighted mean rate (total exacerbations in the study group/total person time in the group)
Additional:
1. Time to first exacerbation
2. Percentage of study group with an exacerbation
3. Total corticosteroid dose (mg/patient/unit of time, and duration of treatment)
Utilization events (ED or UC
visits, hospitalizations, ICU
admissions, intubations)
Number of events/participant/year Percentage of study group with an event
Deaths (asthma specific and
all cause)
Percentage of study group with an event
Validated assessment
measures for studies in acute-
care settings
Methods: PASS, PS, PRAM, CAS, PI, ASS, symptom scores (see text); reported as defined by the scores
used in the measure
ASS, Asthma Severity Score1; CAS, Clinical Asthma Score2 ; ED, emergency department; mg, milligram(s); PASS, Pediatric Asthma Severity
Score3; PI, Pulmonary Index4 ; PRAM, Preschool Respiratory Assessment Measure5; PS, Pulmonary Score6
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